Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy

Chang, Jennie; Staffa, Judy A.; Parks, Mary; Green, Lanh

doi:10.1002/pds.977

Cited by 132 publications

(91 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…155 However, these figures are likely to underestimate the risk both because they are based on voluntary reporting by healthcare professionals, and because they use as the denominator the number of prescriptions, not the number of individuals using the medication. 152 Rates of fatal and non-fatal rhabdomyolysis reported to the US FDA's postmarketing database were also similar, at less than one case per million prescriptions, for all statins except for cerivastatin 156 ( Table 28). More than 80% of cases reported for each drug when taken as monotherapy resulted in hospitalisation for renal failure and dialysis, and 10% resulted in death.…”

mentioning

confidence: 90%

“…More than 80% of cases reported for each drug when taken as monotherapy resulted in hospitalisation for renal failure and dialysis, and 10% resulted in death. 156 This demonstrates that, although rhabdomyolysis is a rare event, it presents a significant safety issue for statin drugs even when taken as monotherapy; the risk is increased when statins are used in combination with gemfibrozil (Table 29).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and economic evaluation of statins for the prevention of coronary events

Ward

Jones²,

Pandor³

et al. 2007

Health Technol Assess

346

312

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as r...

show abstract

mentioning

confidence: 90%

mentioning

confidence: 99%

A systematic review and economic evaluation of statins for the prevention of coronary events

Ward

Jones²,

Pandor³

et al. 2007

Health Technol Assess

346

312

View full text Add to dashboard Cite

show abstract

“…0.3 per million prescriptions; rosuvastatin, data not available). 65 A more accurate estimate of the incidence of 66 Prescription data were used to identify a cohort of 252,460 lipidlowering drug users from 11 health plans across the USA between January 1998 and June 2001. Hospital data were then used to establish how many of the cohort were admitted to hospital with a diagnosis of rhabdomyolysis.…”

Section: Moderate-dose Statinsmentioning

confidence: 99%

Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation

Ara

Pandor²,

Stevens³

et al. 2009

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.Paying by official purchase order You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in t...

show abstract

“…Despite such a low incidence rate, certain drugs such as amiodarone that this patient has been taking to control ventricular rate could increase the risk of rhabdomyolysis when combined with statins [16]. In fact, a review of the United States Food and Drug Administration post-marketing database of rhabdomyolysis (CK 10,000) showed that, of 866 cases reported between 1987 and 2001, 44% were related to combination therapy, as compared with statins alone [22]. The rosuvastatin specification mention that according to the FDA, the risk of myopathy during rosuvastatin therapy may be increased in Asian Americans because Asians appear to process the drug differently, half the standard dose can have the same cholesterol-lowering benefit in those patients, though a full dose could increase the risk of side-effects, which was indicated by the drug's manufacturer, AstraZeneca.…”

Section: Discussionmentioning

confidence: 99%

Iatrogenic AKI and Agranulocytosis: a Cautious Tale of Medication Use in Elderly Patients

Qin¹,

Cang²,

Liu³

et al. 2017

J Clin Exp Nephrol

View full text Add to dashboard Cite

A 83-year-old female patient suffered from acute kidney injury a month after percutaneous coronary intervention. Two weeks before hospitalization, she experienced nausea and intermittent watery diarrhea. Laboratory test showed high levels of serum creatine kinase and lactate dehydrogenase, which were remarkably decreased after ceasing rosuvastatin and valsartan treatment. Despite the recovery of renal function, unfortunately one week later, she was diagnosed with agranulocytosis because of antibiotic therapy. When we stopped meropenem and switched to granulocyto-colony stimulating factor treatment, her white blood cell count returned to a normal range. In our case, both rhabdomyolysis and agranulocytosis were induced by drugs. We provided a literature review of the causes of acute kidney injury and the pathogenesis of rhabdomyolysis and agranulocytosis. We discussed how drugs might lead to these complications. This case highlights the need to be aware of the potential side effects of drugs, especially those given to elderly patients who are likely to be receiving several medications concurrently for managing chronic diseases.

show abstract

Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy

Cited by 132 publications

References 16 publications

A systematic review and economic evaluation of statins for the prevention of coronary events

A systematic review and economic evaluation of statins for the prevention of coronary events

Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation

Iatrogenic AKI and Agranulocytosis: a Cautious Tale of Medication Use in Elderly Patients

Contact Info

Product

Resources

About